NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for use in oncology and immunology, announced an oral presentation of clinical data for the Company’s lead product candidate, KTN3379, at the upcoming 2016 ASCO Annual Meeting, which will take place in Chicago, IL, June 3-7, 2016. KTN3379 is a novel antibody that blocks the activity of the ErbB3 (HER3) receptor by binding to a unique epitope that effectively locks the ErbB3 receptor in an inactive conformation. In addition, KTN3379 has been engineered to extend serum half-life and is being evaluated in multiple combinations with targeted therapies for the broad potential treatment of solid tumors. Clinical data from an ongoing 4-arm Phase 1b clinical trial of KTN3379 in combination with targeted therapies will be presented at ASCO. Kolltan plans to initiate a Phase 2 clinical trial this year based in part on data derived from this Phase 1b clinical trial.
Details of the presentation are as follows:
Oral Presentation Title: Safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted therapies (Abstract 2501)
Speaker: Gerald Steven Falchook, MD, MS, Sarah Cannon Research Institute
Date & Time: Monday, June 6, 2016; 8:12 AM - 8:24 AM CDT
Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Location: Room E354b, McCormick Place, Chicago, IL
Authors: Gerald Steven Falchook, Todd Michael Bauer, Patricia LoRusso, Joseph Francis McLaughlin, Theresa LaVallee, Ronald Alan Peck, Joseph Paul Eder. Sarah Cannon Research Institute, Denver, CO; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Kolltan Pharmaceuticals, New Haven, CT; Yale University-Yale Cancer Center, New Haven, CT
To obtain the full text of the presentation abstract, please visit the 2016 ASCO meeting website link here.
KTN3379 is a human monoclonal antibody designed to block the activity of ErbB3 (HER3), a receptor tyrosine kinase (RTK) that belongs to the epidermal growth factor receptor, or EGFR, family. ErbB3 is believed to be an important receptor regulating cancer cell growth and survival. ErbB3 is expressed in many cancers, including head and neck, breast, lung, gastric, and melanoma. Kolltan is conducting multiple clinical trials evaluating KTN3379 in the treatment of solid tumors (NCT02014909, NCT02456701, and NCT02473731).
About Kolltan Pharmaceuticals
Kolltan, a privately held clinical-stage company, is focused on the discovery and development of novel, antibody-based drugs targeting RTKs for the treatment of cancer and other diseases with significant unmet need. Kolltan’s founders and members of its management team have deep expertise and a proven track record in drug discovery, development, and commercialization of innovative therapeutics, including drugs targeting RTKs. Kolltan is working in close collaboration with the laboratory of Kolltan Co-Founder Dr. Joseph Schlessinger, as well as the Yale University medical and scientific community. The Company has a broad and novel oncology and immunology portfolio of therapeutic biologics targeting multiple RTKs that are advancing in the clinic and are expected to generate multiple near-term milestones.
Forward Looking Statements Disclosure
Any statements in this news release about future expectations, plans, and prospects for Kolltan constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of a variety of important factors. Kolltan anticipates that subsequent events and developments may cause its views to change. However, while Kolltan may elect to update these forward-looking statements in the future, Kolltan specifically disclaims any obligation to do so.